Article Type
Changed
Fri, 01/04/2019 - 11:08
Display Headline
Dabrafenib in advanced melanoma with BRAF V600E mutation

Dabrafenib was recently approved by the US Food and Drug Administration for treatment of unresectable or metastatic melanoma with BRAF V600E mutations as detected by an FDA-approved test. The THxID BRAF assay, for detection of BRAF V600E mutations was concurrently approved. Dabrafenib is not indicated for the treatment of patients with wild-type BRAF melanoma, because of the potential risk of tumor promotion. About 50% of melanomas have an activating mutation in the BRAF gene, with about 80%-90% of those having a V600E mutation, and 10%-20% having a V600K mutation.

 

Click on the PDF icon at the top of this introduction to read the full article.

 

Article PDF
Author and Disclosure Information

 

 

Issue
The Journal of Community and Supportive Oncology - 12(2)
Publications
Topics
Page Number
48-49
Legacy Keywords
dabrafenib, melanoma, BRAF V600E, BRAF V600K, BRAF wild type
Sections
Author and Disclosure Information

 

 

Author and Disclosure Information

 

 

Article PDF
Article PDF

Dabrafenib was recently approved by the US Food and Drug Administration for treatment of unresectable or metastatic melanoma with BRAF V600E mutations as detected by an FDA-approved test. The THxID BRAF assay, for detection of BRAF V600E mutations was concurrently approved. Dabrafenib is not indicated for the treatment of patients with wild-type BRAF melanoma, because of the potential risk of tumor promotion. About 50% of melanomas have an activating mutation in the BRAF gene, with about 80%-90% of those having a V600E mutation, and 10%-20% having a V600K mutation.

 

Click on the PDF icon at the top of this introduction to read the full article.

 

Dabrafenib was recently approved by the US Food and Drug Administration for treatment of unresectable or metastatic melanoma with BRAF V600E mutations as detected by an FDA-approved test. The THxID BRAF assay, for detection of BRAF V600E mutations was concurrently approved. Dabrafenib is not indicated for the treatment of patients with wild-type BRAF melanoma, because of the potential risk of tumor promotion. About 50% of melanomas have an activating mutation in the BRAF gene, with about 80%-90% of those having a V600E mutation, and 10%-20% having a V600K mutation.

 

Click on the PDF icon at the top of this introduction to read the full article.

 

Issue
The Journal of Community and Supportive Oncology - 12(2)
Issue
The Journal of Community and Supportive Oncology - 12(2)
Page Number
48-49
Page Number
48-49
Publications
Publications
Topics
Article Type
Display Headline
Dabrafenib in advanced melanoma with BRAF V600E mutation
Display Headline
Dabrafenib in advanced melanoma with BRAF V600E mutation
Legacy Keywords
dabrafenib, melanoma, BRAF V600E, BRAF V600K, BRAF wild type
Legacy Keywords
dabrafenib, melanoma, BRAF V600E, BRAF V600K, BRAF wild type
Sections
Citation Override
JCSO 2014;12: 48-49
Disallow All Ads
Alternative CME
Article PDF Media